Manchas de la edad

Acemannan stimulates osteoblastic differentiation markers (BMP-2, RUNX2, ALP, COL1) and promotes alveolar bone, cementum, and periodontal ligament regeneration. Clinical trials in dental contexts show enhanced bone dimensional stability. Evidence is focused on alveolar/craniofacial bone rather than systemic bone density.

Ca-AKG has been tested in a human RCT in postmenopausal women (6 g/day for 6 months), showing reduced bone resorption markers and modest improvements in lumbar bone mineral density. AKG acts as a cofactor for prolyl hydroxylase, which is essential for collagen stabilization in bone matrix. Animal models confirm AKG increases bone mass and attenuates age-related bone loss via histone methylation regulation of BMP signaling.

Amaranth is a rich source of calcium, magnesium, phosphorus, and vitamin K — all nutrients essential for bone mineralization and density. Amaranth leaves are noted as an especially high source of vitamin K, which promotes osteoblastic activity. Traditional and nutritional evidence supports a role in preventing osteoporosis, though dedicated human RCTs for bone density specifically are absent.

Anchovies contain calcium (from edible bones), phosphorus, vitamin K, vitamin D, and selenium — all nutrients with established roles in bone mineral density. A PMC study found selenium status to be positively associated with BMD in healthy aging men, independent of thyroid function. A 2024 review confirmed omega-3 PUFAs from fatty fish also show beneficial preclinical and epidemiological signals for bone health.

Anemarrhena and its constituents (timosaponin AIII, mangiferin) have demonstrated anti-osteoporotic effects in ovariectomized mouse models, increasing bone mineral density and modulating bone resorption markers. Network pharmacology and Mendelian randomization analyses support multi-target mechanisms involving PI3K-Akt and VEGF signaling.

Annatto-derived tocotrienols have been studied in a human RCT and multiple animal models for their ability to reduce bone resorption and support bone formation. A 12-week placebo-controlled RCT in 89 postmenopausal women with osteopenia showed significant decreases in bone resorption markers and improvements in bone turnover. Animal data consistently show annatto tocotrienol increases osteoblast activity and reduces osteoclast-driven bone loss.

A 2023 review (PMC10376010) summarized in vitro, animal, and emerging human data showing astaxanthin enhances osteoblast differentiation, inhibits osteoclast activity, and increases bone mineral density. Animal studies confirm BMD and trabecular bone microarchitecture recovery after 6 weeks of ASX supplementation. Human clinical data remain limited but support the mechanistic pathway.

Ethanol extracts of Atractylodes macrocephala rhizome have been shown to inhibit osteoclast differentiation in cell-based and animal models, suggesting bone-protective effects. A 2023 review confirmed that AM root extracts promote osteogenesis and inhibit osteoclastogenesis. No human clinical trials have been published.

Bamboo is one of the richest plant sources of silica, a mineral with documented roles in bone collagen formation and mineralization. Dietary silicon intake is positively associated with bone mineral density (BMD) at the hip in men and pre-menopausal women in the Framingham Offspring and APOSS cohort studies. Silica supports osteoblast activity and stimulates collagen cross-linking in the bone matrix.

Icariin, Barrenwort's primary flavonoid, has been tested in a 24-month randomized double-blind placebo-controlled trial in postmenopausal women, demonstrating beneficial effects on bone mineral density (BMD) with low side effects. Icariin promotes osteoblast differentiation and mineralization while inhibiting osteoclast-mediated bone resorption via estrogen receptor ERα and RANKL/RANK signaling. Multiple systematic reviews and meta-analyses confirm modest but consistent improvements in lumbar spine and femoral neck BMD.

Bovine collagen peptides have been associated with reduced bone density loss in reviews and multi-study assessments. Adequate protein intake, including from beef sources, is a recognized contributor to skeletal health and prevention of osteoporosis.

A Bayesian meta-analysis of five studies (n=12,521) found dietary beta-carotene associated with reduced loss of bone mineral density (RR 0.89; 95% CrI 0.77–0.99). Postmenopausal women show the most consistent positive associations between beta-carotene intake and lumbar spine bone mass. Preclinical work demonstrates beta-carotene inhibits osteoclastogenesis via suppression of the NF-κB/RANKL signaling pathway.

Black cohosh (Actaea racemosa) has been used by Native Americans for musculoskeletal and menopausal symptoms. Clinical research suggests the extract increases bone-specific alkaline phosphatase, a marker of bone formation, and a double-blind placebo-controlled study found measurable effects on bone turnover markers in postmenopausal women.

Epidemiological evidence associates habitual black tea consumption with preservation of bone mineral density, particularly in postmenopausal women. Animal models show thearubigins and black tea extract inhibit osteoclast activity and reduce bone loss. Human clinical data remain predominantly epidemiological rather than from interventional trials.

Blackberries are a notable source of vitamin K, which supports bone mineralization and is linked to reduced fracture risk in prospective studies. Blackberry phenolics (ellagic acid, anthocyanins) have demonstrated in vivo protection against bone loss. A meta-analysis of 13 RCTs found anthocyanin-rich food consumption significantly increased lumbar spine bone mineral density.

Small RCTs and observational cohorts link higher anthocyanin and blueberry intake with greater bone mineral density (BMD). A crossover RCT in postmenopausal women found freeze-dried blueberry increased net bone calcium retention versus no treatment.

An animal model of senile osteoporosis found that lifelong supplementation with borage and fish oils decreased inflammation and improved bone parameters. No human RCT specifically evaluating borage oil for bone mineral density has been identified in peer-reviewed sources. Evidence remains preclinical.

Boron is a trace mineral that modulates vitamin D hydroxylation, delays estrogen and vitamin D degradation, and influences calcium and magnesium metabolism relevant to bone. The NIH ODS and National Academy of Sciences include boron among micronutrients relevant to bone metabolism, and boron deprivation impairs bone composition in animal studies. However, direct large-scale RCT evidence for BMD improvement in humans remains limited.

Brussels sprouts are exceptionally rich in vitamin K1 (~270% DV per cup cooked), which is essential for activating osteocalcin — the protein that binds calcium into the bone matrix. They also supply folate that supports homocysteine reduction, as elevated homocysteine is independently associated with reduced BMD and increased fracture risk.

A 2018 in vivo study using ovariectomized (OVX) rats demonstrated that high-dose B. falcatum extract partially prevented estrogen deficiency-induced bone loss by inhibiting osteoclast formation through iNOS/NO signaling, suppressing transcription factors c-Fos and NFATc1. This is preclinical data; human studies are not available.

Calcium is the primary mineral constituent of bone and the most extensively studied supplement for bone density. Meta-analyses of RCTs demonstrate that calcium supplementation significantly improves bone mineral density (BMD), particularly in people under 35 building peak bone mass. Combined with vitamin D, it attenuates bone loss in older adults, though fracture-risk reduction in the elderly remains modest.

Casein plays a unique role in calcium transport and absorption via casein phosphopeptides (CPPs), which prevent the formation of insoluble calcium salts and enhance calcium bioavailability in the small intestine. Epidemiological and clinical data link higher dairy protein (including casein) intake to greater bone mineral density. Enzyme-specific casein hydrolysates have been shown to enhance calcium absorption and osteoblast activation.

EGCG has been shown to reduce bone loss in preclinical models by modulating the RANK/RANKL/OPG pathway, promoting osteogenic differentiation, and inhibiting osteoclastogenesis. Epidemiological and clinical evidence suggests green tea consumption is associated with improved bone mineral density, particularly in postmenopausal women.

Cauliflower contains vitamin K1 (phylloquinone), which is a cofactor for osteocalcin carboxylation essential for bone mineralization. It also provides vitamin C, which supports collagen synthesis in the bone matrix. Both nutrients have documented associations with bone mineral density in human studies.

Chia seeds are a notable source of calcium (456–671 mg/100 g), phosphorus, and magnesium — all key minerals for bone matrix formation. Long-term feeding studies in rodents show increased bone mineral content with chia. Human clinical data on bone density outcomes directly attributable to chia are limited.

Chicory-derived inulin-type fructans enhance intestinal calcium and magnesium absorption in both adolescents and postmenopausal women, with one year of supplementation in adolescents producing measurable gains in bone mineral content and density. The FDA has reviewed and acknowledged scientific evidence linking inulin-type fructans to bone mineral density benefits.

Danshen compounds promote osteoblast activity and inhibit osteoclast-mediated bone resorption, with clinical trial data showing BMD improvement and bone biomarker normalization in osteoporosis patients. Both tanshinone (lipophilic) and salvianolic acid (hydrophilic) fractions contribute through distinct but complementary mechanisms.

Chondroitin sulfate (CS) has been studied in animal models for its ability to increase bone mineral density (BMD) and improve bone microstructure. In diabetic rat models, CS administration significantly increased BMD and reduced bone marrow adipocyte number. A separate rat study demonstrated that CS intervention inhibits osteoclast differentiation, promotes calcium absorption, and raises femoral calcium content in calcium-deficient animals. Direct human RCT data specifically targeting BMD are lacking, making existing evidence primarily preclinical.

Cissus quadrangularis (Hadjod in Ayurveda) has been used in Indian traditional medicine for bone fracture healing for millennia. A 2025 systematic review and meta-analysis confirmed that CQ supplementation positively affects bone-related biomarkers in humans, and it is identified in multiple botanical osteoporosis reviews as having clinically meaningful evidence for bone health.

Preclinical models consistently show CLA—particularly the t10,c12 isomer—can enhance bone mineral density by promoting osteoblast activity and inhibiting osteoclast-mediated resorption. Human clinical trial evidence is limited and inconsistent, though preliminary data from RA patients show benefits on bone markers.

Cod liver oil provides vitamin D, which is essential for intestinal calcium absorption and bone mineralization. Studies show vitamin D supplementation from CLO supports bone mineral density maintenance and reduces fracture risk, particularly in older adults and those at risk for osteoporosis.

A 12-week double-blind RCT in overweight and obese men found that forskolin administration significantly increased bone mass compared to placebo, as measured by DXA. This is the only published human in vivo study directly assessing this relationship. The proposed mechanism involves cAMP-driven activation of osteoblasts.

Collagen (type I) constitutes approximately 90% of the organic bone matrix and provides the scaffold for mineral deposition. A 2018 double-blind RCT in 131 postmenopausal women found that 5 g/day specific collagen peptides for 12 months significantly increased BMD at the femoral neck and spine versus placebo, with elevated bone formation markers. A 2025 meta-analysis of four RCTs confirmed this benefit.

Collard greens are exceptionally rich in vitamin K (over 880% DV per cooked cup) and provide significant calcium (~27% DV per cooked cup), both of which are critical for bone mineralization. Vitamin K activates osteocalcin and other proteins essential for calcium incorporation into bone matrix. Observational studies link low vitamin K intake to increased fracture risk.

Bovine colostrum contains IGF-1, growth hormone-stimulating fractions, and colostrum basic protein (CBP) that have been shown in animal studies to increase bone mineral density and osteoblast markers. A 2025 RCT in adults aged 55–70 found trends toward improved bone turnover markers with a colostrum-containing supplement. Human evidence remains preliminary, with most mechanistic data from preclinical models.

Copper is an essential cofactor for lysyl oxidase, the enzyme responsible for crosslinking collagen and elastin fibers in the bone matrix. Copper deficiency causes bone abnormalities including osteoporosis-like lesions and impaired collagen crosslinking. The NIH ODS and National Academy of Sciences recognize copper as a micronutrient relevant to bone metabolism and it is consistently included in evidence-based bone supplementation protocols.

Several RCTs indicate creatine supplementation combined with resistance training may attenuate age-related bone mineral density loss and increase bone area in older adults, though the independent effect of creatine beyond exercise alone remains contested. A meta-analysis of five RCTs found no statistically significant added benefit of creatine over resistance training alone on BMD at major sites. Benefits appear exercise-dependent.

Clinical trials of creatine monohydrate combined with resistance training in older adults have produced mixed results for bone mineral density. High-dose protocols with resistance training show some modest benefit in specific sites, but a 2-year RCT in postmenopausal women with osteopenia found no improvement with creatine alone, and a 2026 meta-analysis confirmed bone density was unchanged overall.

Multiple human epidemiological studies and a meta-analysis of 15 studies (100,496 individuals) associate higher β-cryptoxanthin intake with significantly reduced osteoporosis risk (OR=0.79, 95% CI 0.70–0.90). In vitro work shows β-cryptoxanthin directly stimulates osteoblastic bone formation and inhibits osteoclastic bone resorption. Animal studies confirm prevention of ovariectomy-induced bone mineral density loss at doses of 50–100 µg/kg.

Daidzein is a soy isoflavone that binds bone estrogen receptors and is the metabolic precursor to equol, a more potent bone-active phytoestrogen. Animal research demonstrated daidzein was more efficient than genistein in preventing ovariectomy-induced bone loss. Clinical trials of isoflavone preparations containing daidzein show positive effects on BMD in postmenopausal women.

Daidzin and its metabolites (especially daidzein and equol) show bone-sparing effects in preclinical models of estrogen deficiency by promoting osteoblastogenesis and inhibiting osteoclastogenesis via estrogen receptor-dependent mechanisms. Animal data are consistent; clinical evidence derives primarily from mixed isoflavone trials.

DHEA decline with age correlates with reduced bone mineral density, and clinical trials show modest BMD benefits, primarily in women. A pooled analysis of four RCTs found significant lumbar spine and trochanter BMD increases in older women receiving 50 mg/day DHEA versus placebo. Effects in men are less consistent. The mechanism involves inhibition of catabolic IL-6 and stimulation of anabolic IGF-I pathways, as well as conversion to estradiol.

Preclinical studies with Dioscorea alata extract and dioscorin demonstrate increased bone mineral density and osteoblast differentiation in ovariectomised mouse models. The mechanism involves estrogenic activity via ovarian aromatase upregulation. Human evidence is lacking.

Cuscuta chinensis extract has demonstrated anti-osteoporotic effects in multiple preclinical studies, increasing bone mineral density and modulating the RANKL/OPG signaling axis. Active constituents kaempferol and hyperoside promote osteoblast activity and inhibit osteoclast differentiation. This is one of the best-characterized pharmacological actions of dodder in the scientific literature.

Cornus officinalis has been specifically studied as a TCM treatment for osteoporosis, with extensive preclinical evidence for promoting osteoblast differentiation, inhibiting osteoclastogenesis, and improving bone mineral density in animal models. Multiple PMC reviews identify anti-osteoporosis as a primary pharmacological effect.

Epidemiological studies show habitual tea drinkers have higher bone mineral density and lower hip fracture risk. EGCG promotes osteoblast differentiation and mineralization while suppressing osteoclastogenesis via the RANKL/OPG pathway in multiple cell and animal studies. Human population data are supportive but isolated EGCG RCT data for bone density specifically remain limited.

Eggs provide vitamin D and high-quality protein—two key nutrients for bone mineralization. Cross-sectional and observational studies associate whole egg consumption with favorable bone mineral density, particularly in children, and a scoping review positions eggs as a dietary contributor to maintaining bone health in aging individuals.

Preclinical evidence—including in vitro and animal studies—indicates eleuthero-containing preparations can inhibit osteoclast activity and protect against inflammatory bone loss. The clinical translation remains preliminary, with available evidence from a multi-herb combination (Vigeo) rather than eleuthero alone.

A 2025 systematic review and meta-analysis of 18 RCTs in osteoporotic rat models found eucommia extract significantly improved BMD (SMD=2.44), trabecular number, and bone volume fraction. Preliminary human clinical studies using eucommia-based formulations reported improved BMD and reduced bone resorption markers. Active constituents including aucubin, geniposide, and rutin promote osteoblastogenesis and inhibit osteoclastogenesis via BMP/SMAD, Wnt/β-catenin, and RANKL/OPG pathways.

A limited number of RCTs have examined EPO combined with fish oil and calcium for bone mineral density (BMD). One controlled trial in elderly women with osteopenia/osteoporosis found significant BMD maintenance and a modest spinal density gain over 18–36 months. Evidence is sparse and findings are not consistently replicated in healthy populations.

Ferulic acid suppresses osteoclast differentiation and bone resorption via inhibition of RANKL-dependent NF-κB signaling. In a glucocorticoid-induced osteoporosis neonatal rat model, FA at 20 and 30 mg/kg increased bone mineral density by 25% and 141.7%, respectively. Evidence is preclinical; no human BMD trials have been published.

Fisetin attenuated age-related bone density loss in a progeria mouse model (Zmpste24−/− mice), significantly improving bone mineral density and trabecular bone scores via its senolytic mechanism. A separate study found fisetin promotes osteogenesis in vitro. No human trials exist.

Preclinical and some human epidemiological evidence suggests flaxseed and its oil may support bone mineral density via ALA omega-3 fatty acids and phytoestrogen lignans. Epidemiological studies associate higher ALA intake with better bone health in aging populations, though direct human RCT data on whole flaxseed and BMD remain limited.

Forskolin activates adenylate cyclase similarly to parathyroid hormone signalling in bone cells, and a 12-week RCT in overweight men found a statistically significant increase in bone mass in the forskolin group versus placebo as measured by DXA. This represents the first in vivo human evidence for this effect.

Preclinical research has demonstrated that a water extract of Forsythia suspensa reduces bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclast formation and resorption. It suppresses key osteoclast differentiation signaling pathways involving p38 and JNK. Evidence is currently limited to animal models; no human clinical trials on bone density exist.

FOS fermentation produces SCFAs that lower colonic pH, increasing solubility and passive absorption of calcium and magnesium, a mechanism confirmed in both animal and human studies. Human trials show improved calcium absorption, particularly in adolescents and postmenopausal women, though effects on bone mineral density (BMD) itself are modest or inconsistent at the durations tested. Short-chain FOS combined with calcium supplementation affects bone turnover markers in postmenopausal women.

Genistein, the principal soy isoflavone aglycone, inhibits osteoclast bone resorption and stimulates osteoblast differentiation via estrogen receptor-beta binding. A 3-year RCT in osteopenic postmenopausal women showed genistein significantly improved bone formation markers without adverse effects on breast or uterine tissue, and meta-analyses show modest positive BMD effects.

Gentiana macrophylla extract has shown protective effects against osteoporosis in preclinical mouse models. The constituent sweroside promotes sex steroid hormone synthesis via adenylate cyclase activation, contributing to bone metabolism regulation. Loganic acid, also present in G. macrophylla, prevented OVX-induced bone mineral density loss in osteoporotic mice.

A pilot RCT found that GLA combined with EPA and calcium significantly preserved and increased lumbar spine and femoral bone mineral density (BMD) in elderly women versus calcium alone over 18–36 months. Animal work shows GLA and EPA enhance calcium absorption and deposition in bone. Evidence is limited but encouraging.

Anti-osteoporosis effects are directly attributed to glycitin/glycitein in published reviews, consistent with its phytoestrogenic SERM activity. Soy isoflavones as a class have been studied in multiple clinical trials and a 2016 systematic review of 23 RCTs (n=3,494) concluded that phytoestrogen supplementation can probably prevent the reduction in BMD during menopause. Glycitin is consistently present in the isoflavone preparations tested, though its independent contribution to bone effects has not been isolated.

Epidemiological and clinical data suggest green tea consumption is associated with higher bone mineral density (BMD) and lower risk of osteoporosis and fracture, particularly in postmenopausal women. A Korean nationwide study of 3,530 postmenopausal women found those drinking 1–3 cups daily had significantly lower prevalence of osteopenia and osteoporosis. Proposed mechanisms include stimulation of osteoblast activity and suppression of osteoclast activity via EGCG and antioxidant effects.

Hesperidin promotes osteogenesis by upregulating osteogenic markers and organizing collagen matrix in bone tissue. A clinical trial (NCT01881204) evaluated hesperidin combined with calcium for bone health in postmenopausal women. Preclinical studies in diabetic rats show hesperidin reduces pro-inflammatory bone resorption markers and increases bone turnover markers osteocalcin and osteopontin.

Lignans, including those metabolized to enterolactone, interact with estrogen receptor beta (ER-β), which is important for bone maintenance. Reviews and broad lignan research support a role in attenuating post-menopausal bone loss. Specific HMR human bone density trials have not been published, but the mechanism via estrogenic modulation is established.

Phytoestrogens including lignans are studied as potential bone-protective agents, particularly in postmenopausal women, due to their partial ERβ agonist activity which may slow estrogen-withdrawal-driven bone resorption. Preliminary research suggests HMR lignans may slow bone loss, but specific HMRlignan RCT bone density data have not been published. Large cohort data on dietary lignans and bone density have been inconsistent.

8-Prenylnaringenin (8-PN) from hops, acting via estrogen receptor-alpha, has been shown to protect against bone loss following estrogen depletion in murine models. Preclinical evidence suggests anti-resorptive properties. Clinical investigation of bone outcomes has been initiated as part of post-menopausal health studies.

Horsetail (Equisetum arvense) contains among the highest concentrations of bioavailable silica of any plant, a mineral integral to bone formation and remodeling. Silica is proposed to stimulate osteoblasts and inhibit osteoclasts, thereby supporting bone mineral density. A small clinical trial in postmenopausal women with osteoporosis showed significant increases in bone density after up to one year of treatment with a titrated horsetail dry extract. Evidence is preliminary and limited to small, imperfectly controlled studies.

Preclinical research identifies hyacinth bean as having potential to inhibit bone density loss and promote bone union, with suggested applicability to osteoporosis management. This is documented in multiple peer-reviewed nutrition and food science reviews drawing on animal study data.

Icariin is the principal bioactive flavonoid glycoside from Epimedium (horny goat weed), used for bone tonification in TCM for over 1,400 years. A 2-year RCT in 85 late postmenopausal women showed epimedium extract (60 mg icariin/day) significantly increased femoral neck BMD by 1.6% and lumbar BMD by 1.3% versus placebo decreases. It promotes osteoblastogenesis and inhibits osteoclastogenesis via estrogen receptor and Wnt/BMP pathways.

Clinical trials demonstrate that oligofructose-enriched inulin (e.g., Synergy1) increases fractional calcium absorption in adolescents and postmenopausal women, with at least one one-year trial showing improved bone mineral content. The mechanism involves colonic acidification by SCFAs enhancing passive calcium solubility and transport. Effects on direct bone mineral density as measured by DEXA are less consistently demonstrated.

Ipriflavone is a synthetic isoflavone derived from daidzein with documented effects on bone density in multiple placebo-controlled trials. A 1997 RCT showed vertebral bone density declined 4.9% in the calcium-only group but was unchanged in ipriflavone-treated women. It is approved as an osteoporosis treatment in Japan and several European and Asian countries, though a large 3-year multisite RCT found it no more effective than placebo.

Kale is one of the richest dietary sources of vitamin K1 and also provides calcium and magnesium. Vitamin K1 is required for carboxylation of osteocalcin, a key bone matrix protein. Meta-analyses of RCTs show combined vitamin K and calcium supplementation has a modest positive effect on lumbar bone mineral density and reduces undercarboxylated osteocalcin.

Kudzu root contains phytoestrogenic isoflavones (puerarin, daidzein, daidzin) that act similarly to selective estrogen receptor modulators (SERMs), potentially slowing bone resorption. A randomized clinical trial in menopausal women found statistically significant reductions in bone resorption markers (CTX-I) after 4 weeks of kudzu extract. Traditional use also recognizes kudzu's role in preserving bone health around menopause.

Bone organic matrix is approximately 90% type I collagen, making proline a structural requirement for bone quality and mineral deposition. Clinical RCTs of proline-rich collagen peptides in postmenopausal women have shown significant improvements in bone mineral density (BMD) at the spine and femoral neck versus placebo. A 2025 meta-analysis of RCTs confirmed that collagen peptide supplementation significantly augments BMD, particularly when combined with calcium and vitamin D.

L. rhamnosus GG has been shown to ameliorate bone loss and improve bone microarchitecture in animal models via Th17/Treg immune regulation. The gut-bone axis is a recognized pathway whereby gut microbiota modulate osteoclast formation through immune signaling. Postmenopausal osteoporosis models in rodents show protective effects of LGG on trabecular bone. Human clinical evidence remains largely indirect via the broader probiotic-bone literature.

Preclinical and early clinical data indicate lactoferrin promotes osteoblast activity and suppresses osteoclast resorption, protecting bone mineral density. Animal studies demonstrate preservation of trabecular architecture and BMD in ovariectomized rats. Human clinical trial evidence specifically measuring BMD as a primary outcome remains limited.

Lignans may promote bone health through interaction with estrogen receptor beta, which is expressed in osteoblasts. Consumption of flaxseed in various forms has exhibited positive effects on bone mineral density in different animal models and in several clinical studies. A double-blind RCT in menopausal women evaluated flaxseed supplementation effects on bone mineral density.

Lycopene has been investigated for its effects on bone mineral density (BMD) and bone turnover markers, particularly in postmenopausal women. A 2025 systematic review (PROSPERO-registered, PRISMA-guided) evaluated clinical and preclinical evidence showing effects on BMD, osteocalcin, and bone resorption markers. The proposed mechanism involves suppression of oxidative stress-driven osteoclast activation.

Preclinical studies demonstrate that maca, particularly red and black ecotypes, prevents estrogen-deficient bone loss and improves bone mineral density in ovariectomized rat models. A constituent, N-benzyl-palmitamide, promotes osteoblast proliferation via estrogen receptor pathways. No human RCTs have confirmed these effects.

Magnesium is an essential cofactor in bone mineral metabolism, enzyme activity for bone matrix synthesis, and is required for vitamin D activation. Observational data from large cohort studies found higher magnesium intake associated with 2–3% greater bone density in women. Clinical trials including the COMB study show supplementation may attenuate bone loss.

Manganese is a required cofactor for glycosyltransferases involved in proteoglycan synthesis in bone matrix and for superoxide dismutase protecting osteoblasts. The NIH ODS and National Academy of Sciences recognize it as an essential trace element for bone health, with deficiency causing skeletal abnormalities in animal models.

MCHC is a bovine-bone-derived supplement providing calcium, phosphorus, collagen, and bone growth factors in a form structurally similar to human bone mineral. Several RCTs found MCHC supplementation led to slower BMD loss in postmenopausal women compared to calcium carbonate or placebo, particularly when combined with vitamin D.

Clinical RCTs indicate melatonin supplementation may increase bone mineral density, particularly at the femoral neck, in postmenopausal women with osteopenia. Mechanistically, melatonin promotes osteoblast differentiation and suppresses osteoclastogenesis via MT2 receptors. Evidence is promising but limited by small trial numbers and high heterogeneity.

Finger millet has exceptional calcium content (up to 364 mg/100g) and clinical evidence demonstrates improved bone mineral density and reduced bone resorption markers with millet supplementation. A trial in premenopausal women showed significant improvements in BMD and serum calcium after finger millet supplementation. A systematic review found calcium retention of 23.4% in children consuming finger millet-based diets.

Multiple preclinical studies demonstrate that Morinda officinalis root extracts and saponins promote osteoblast differentiation, increase bone mineral density, and inhibit osteoclast activity via BMP-SMAD and NF-κB pathways. Animal models of ovariectomy-induced osteoporosis show significant protection of bone mass. Human clinical evidence is indirect but the mechanism is well-characterised.

Naringin consistently promotes osteoblast differentiation and inhibits osteoclastogenesis in preclinical models, improving BMD and trabecular parameters. A 2021 meta-analysis of 10 animal studies showed significantly increased BMD after naringin treatment (WMD 0.06; 95% CI 0.03–0.09). Multiple signaling pathways—Wnt/β-catenin, JAK2/STAT3, BMP-2/Runx2—mediate these effects. Human clinical evidence is not yet available.

OA exerts osteoprotective effects in ovariectomized mice and aged female rats, significantly increasing bone mineral density, improving bone microarchitecture, enhancing calcium balance, and modulating vitamin D metabolism via renal CYP27B1 upregulation.

Preclinical research shows that olive polyphenols protect from bone loss by promoting osteoblast activity. A double-blind RCT in postmenopausal women with osteopenia found that 12 months of a specific olive polyphenol extract (Bonolive®) increased serum osteocalcin and may stabilize lumbar spine BMD. Evidence is preliminary but grounded in human data.

Human cross-sectional and cohort studies demonstrate a positive association between olive oil intake and volumetric bone mineral density (vBMD). A Spanish women cohort found significant positive correlations between olive oil intake and total, trabecular, and cortical bone density. Human studies show daily olive oil consumption can prevent decline in bone mineral density.

Epidemiological evidence links higher omega-3 intake to better bone mineral density (BMD), and mechanistic studies suggest EPA/DHA enhance calcium absorption and inhibit bone resorption. Clinical RCT evidence is mixed, with some trials showing BMD benefits particularly in younger and osteopenic women, but overall insufficient to confirm a treatment effect for osteoporosis.

Onion flavonoid extracts have demonstrated anti-osteoporotic activity in preclinical models, with a twofold increase in bone mineral density reported in ovariectomized rats. Population-level data show that women who consume onions more frequently have higher bone density. Onion's flavonoids promote osteoblast proliferation and inhibit RANKL-induced osteoclastogenesis.

Ophiopogonin D inhibits osteoclastogenesis and protects against bone loss in preclinical models, acting via suppression of NFATc1 and TRAP under oxidative stress, and reducing ROS levels critical to osteoclast formation. Multiple reviews identify osteoprotective activity as a documented effect of OP-D.

Hesperidin from orange has been shown in experimental models to regulate bone metabolism through Wnt/β-catenin signalling, promote osteogenic differentiation, and protect against bone loss. In rat models, hesperidin intake resulted in bone mass gain and protection against ovariectomy-induced bone loss. Human clinical evidence is limited.

Palm oil-derived tocotrienols have demonstrated bone-protective effects in multiple animal models of osteoporosis, improving bone mineral density (BMD), trabecular architecture, and markers of bone turnover. Early clinical evidence from a RCT in postmenopausal women with osteopenia showed tocotrienol supplementation reduced bone resorption biomarkers. Human clinical trial data remain limited but supportive.

Parsley is exceptionally rich in vitamin K, with a half-cup (30 g) providing over 500% of the RDI. Vitamin K activates osteocalcin and other bone matrix proteins, supporting bone mineralisation and density. The herb also supplies calcium, magnesium, and folate. Adequate vitamin K intake is scientifically associated with higher bone mineral density and reduced fracture risk.

Berberine from P. amurense has undergone small-scale clinical trials for osteoporosis and has been shown to improve bone density in postmenopausal patients and reduce bone turnover markers. Phellodendron species (including P. amurense) are reviewed in a 2024 Chinese Journal of Integrative Medicine paper as promising for osteoporosis via berberine and palmatine's bone-protective properties.

Phosphorus is the second most abundant mineral in bone, forming hydroxyapatite with calcium as the primary mineral matrix of skeletal tissue. Adequate dietary phosphorus is universally recognized as essential for bone mineralization and maintaining BMD by major health bodies including the NIH and WHO. Deficiency causes rickets in children and osteomalacia in adults.

A randomized double-blind placebo-controlled trial (Oligopin pine bark extract) in postmenopausal women with osteopenia showed improved oxidative stress markers and bone turnover markers. MSKCC cites this study, and pine bark extract is considered a supportive agent for bone health, particularly in postmenopausal women.

Preclinical and some clinical evidence suggests pomegranate's phytoestrogens and polyphenols may support bone density, particularly relevant in postmenopausal women. Pomegranate seed oil contains punicic acid and phytoestrogens, and clinical trials in menopausal women have explored its effects on bone markers.

Higher dietary potassium intake is associated with greater bone mineral density (BMD) in observational studies, particularly in postmenopausal women. The proposed mechanism involves potassium's alkalinizing salts neutralizing diet-induced acid load, thereby reducing calcium mobilization from bone. RCT evidence with potassium citrate shows reduced bone resorption markers.

Multiple animal studies demonstrate FLL increases bone mineral density and improves bone microarchitecture, particularly in ovariectomized and aged female rats. Key active constituents are oleanolic acid, ursolic acid, salidroside, and nuzhenide. No human clinical trials have been conducted.

Progesterone and progestins contribute to bone mineral density (BMD) by stimulating osteoblast activity via progesterone receptors on bone cells. A systematic review and meta-analysis of five RCTs (n=1,058 postmenopausal women) found estrogen-progestin therapy yielded +0.68%/year greater spinal BMD gain than estrogen alone. Women with anovulatory cycles lose approximately 1% vertebral BMD per year, implicating progesterone deficiency in bone loss.

Multiple RCTs demonstrate that daily prune consumption (50–100 g) preserves and in some cases improves bone mineral density (BMD) in postmenopausal women. The Prune Study—a 12-month RCT in 235 women—found 50 g/day prevented hip BMD loss, with effects persisting at 12 months. A comprehensive review of 24 preclinical and clinical studies supports prune's role in reducing bone resorption and promoting bone formation.

Quinoa is notably rich in phosphorus, magnesium, manganese, calcium, and zinc—key minerals for bone matrix formation and maintenance. Phosphorus and zinc from quinoa provide 40–60% of adult daily requirements per 100 g. Manganese is essential for bone collagen cross-linking. Germination significantly increases calcium content (~49%). Dietetic guidelines reference quinoa's mineral profile in managing bone density risk in celiac disease.

Red clover isoflavones have been clinically investigated for their ability to slow bone mineral density (BMD) loss in postmenopausal women. A 12-week randomized, double-blind, placebo-controlled trial (n=60) showed that only the placebo group experienced a significant decline in lumbar spine BMD. A 3-year safety study also detected differences in bone turnover markers between active and placebo groups. Results across trials are directionally positive but not fully consistent.

Rehmannia Radix Preparata has demonstrated bone-protective effects in animal studies and is supported by clinical pharmacological evidence for postmenopausal and glucocorticoid-induced osteoporosis. It enhances BMD by upregulating osteoblastogenesis and suppressing osteoclastogenesis through estrogen signalling, PI3K-Akt, and TGF-β pathways. An ovariectomized rat study found dried R. glutinosa extract (300 mg/kg) significantly inhibited femoral and lumbar BMD loss.

Multiple preclinical studies show rehmannia extracts preserve bone mineral density and promote osteoblast activity while inhibiting osteoclast activity. The dried root extract (DRGE) at 300 mg/kg for 8 weeks significantly inhibited BMD decline in ovariectomized (OVX) rats without affecting estrogen levels. Clinical use in over 107 osteoporosis trials (in TCM co-prescriptions) has also been documented in a comprehensive review.

Multiple human RCTs demonstrate that resveratrol supplementation can improve bone mineral density (BMD), particularly in postmenopausal women. The 24-month RESHAW trial (75 mg twice daily) showed significant gains in lumbar spine and femoral neck BMD alongside a 7.24% reduction in bone resorption marker CTX-1 versus placebo. A separate RCT in type 2 diabetic patients found resveratrol 500 mg/day prevented whole-body BMD loss seen in placebo recipients. Results across studies are inconsistent but the highest-quality data support a modest bone-protective effect.

Safflower seeds are used in Korean folk medicine to enhance bone formation and prevent osteoporosis. A PMC rat study found oral methanolic safflower seed extract (MESS) significantly increased osteocalcin, bone-specific alkaline phosphatase, IGF-I, and femur/tibia length. HSYA also inhibited bone resorption and promoted bone formation in zebrafish and cell models. A 2025 review classifies safflower as 'osteoporosis-preventative.'

Preclinical data from the 2016 BMC study show EEST protects against LPS-induced bone loss in mice by inhibiting osteoclastogenesis, with micro-CT confirmation of preserved bone structure. This directly supports a role in maintaining bone density. Evidence is animal-model only with no human data.

SDG acts as a phytoestrogen that binds estrogen receptors in bone tissue, counteracting postmenopausal estrogen-deficiency bone loss. A 2023 rodent study using ovariectomized (OVX) rats showed SDG improved bone formation indices and regulated ERα and ERβ expression in femoral tissue. Clinical evidence confirms SDG can increase serum calcium, bone mass, and reduce bone loss in postmenopausal women.

Sesame seeds are a notable dietary source of calcium, zinc, copper, and magnesium — minerals essential for bone mineralization. Literature reviews (PubMed, ScienceDirect, Google Scholar) confirm sesame has a positive impact on bone health in postmenopausal women with osteoporosis. Sesame lignans may also exert phytoestrogenic effects that slow bone resorption. Most mechanistic evidence is preclinical; some supportive human observational data exist.

Shiitake is among the few non-animal food sources of vitamin D2, which is essential for calcium absorption and bone mineralization. UV-irradiated shiitake provides measurable ergocalciferol (D2). A systematic review found UV-irradiated mushroom vitamin D2 effective at raising serum 25(OH)D2, and 9 of 12 animal studies demonstrated bone metabolism benefits. Human bone-specific clinical trials are needed.

Multiple epidemiological studies and intervention trials link higher dietary silicon intake to greater bone mineral density (BMD), particularly at hip sites in men and premenopausal women. Silicon supports bone by stimulating collagen type I synthesis and aiding matrix mineralization. A 12-month RCT found choline-stabilized orthosilicic acid (ch-OSA) combined with calcium/vitamin D improved bone collagen markers in osteopenic women.

Silymarin demonstrates osteogenic activity in cell and animal studies, promoting osteoblast differentiation, alkaline phosphatase expression, and osteocalcin production. An in vitro and animal study found silymarin enhanced bone mineral density in tibia-fractured mice. Human clinical trials specifically for bone density are not yet published.

Polygonatum sibiricum polysaccharide (PSP) has been shown in rodent studies to promote osteoblast differentiation and block osteoclastogenesis via the Wnt/β-catenin pathway, increasing bone mineral density. No human clinical trial has been completed, but the mechanistic animal data are well-documented in peer-reviewed literature.

Meta-analyses of RCTs show soy isoflavones produce statistically significant but modest improvements in lumbar spine bone mineral density (BMD) in menopausal women, and reduce the bone resorption marker urinary deoxypyridinoline. Effects at hip and femoral neck are less consistent. Doses above 75–80 mg/day appear more effective.

Soy isoflavones (principally genistein and daidzein) bind estrogen receptors in bone, stimulating osteoblasts and inhibiting osteoclasts. A systematic review of 18 RCTs in postmenopausal women found significant positive effects on lumbar spine and femoral neck BMD, and they are recognized in osteoporosis literature as botanicals with measurable bone effects at 30–126 mg/day.

Multiple meta-analyses of randomized controlled trials support that soy isoflavones improve bone mineral density (BMD), particularly lumbar spine BMD, in postmenopausal women. A 2019 PubMed meta-analysis of 52 trials found significant BMD improvements at the lumbar spine, hip, and femoral neck with soy isoflavone consumption. Results are most consistent for lumbar spine, with effects at hip sites less uniform. Doses above approximately 75–80 mg/day isoflavones appear most effective.

Spinach is a rich dietary source of vitamin K1 (phylloquinone), which is essential for carboxylation of osteocalcin, a protein that binds calcium to bone matrix. Meta-analyses of RCTs show vitamin K supplementation significantly reduces fracture risk, and spinach's vitamin K content supports the dietary pathway to this benefit.

Strontium, as strontium ranelate, has been studied in large Phase III RCTs (SOTI, TROPOS) demonstrating significant reductions in vertebral fractures (41%) and non-vertebral fractures in postmenopausal women with osteoporosis. Strontium ranelate was approved for osteoporosis treatment in Australia and most of Europe, though restricted in some EU countries due to cardiovascular risks. OTC strontium citrate lacks equivalent RCT data.

CX rhizome extract has been studied in ovariectomized hyperlipidemic rat models for bone loss prevention, showing improvements in osteoblast proliferation and differentiation. Senkyunolide H, a CX phthalide, attenuates osteoclastogenesis and postmenopausal osteoporosis via NF-κB, JNK, and ERK pathway modulation. Bone protection is identified as a pharmacological focus in recent CX reviews.

Multiple preclinical studies have demonstrated that Dipsacus asper extracts and isolated compounds — particularly asperosaponin VI and Dipsacus asper polysaccharides — promote osteoblast differentiation and increase bone mineral density in ovariectomized rat models. These findings support the long-standing TCM use of teasel root for bone diseases. No human clinical trials are available.

Preclinical studies show T. cordifolia prevents ovariectomy-induced bone loss and stimulates osteoblast differentiation and mineralization. Its Beta-ecdysone increases joint cartilage thickness and promotes osteogenic differentiation in mesenchymal stem cells.

In vitro human bone cell cultures demonstrate tocotrienols inhibit osteoclast activity and promote osteoblast differentiation. Animal models of osteoporosis consistently show improved bone mineral density and microstructure with tocotrienol supplementation. Epidemiological evidence associates vitamin E consumption with prevention of age-related bone loss. Dedicated human clinical trials are currently scarce.

Human epidemiological studies and a pilot clinical trial support lycopene's role in protecting bone mineral density. In a controlled pilot study of 39 postmenopausal women, those consuming lycopene-rich tomato sauce daily for 3 months had no significant bone loss, while control women lost bone (p=0.002). Lycopene activates osteogenic pathways (WNT/β-catenin, ERK1/2) and suppresses bone resorption signaling.

GGOH promotes osteoblast differentiation and mineralization while suppressing osteoclastogenesis through RANKL/NFATc1 and MAPK/JNK pathways. Multiple in vitro studies using human osteoblasts and osteoclasts confirm its capacity to restore cell viability suppressed by bisphosphonate drugs. These findings support a mechanistic role for GGOH in maintaining bone density.

Preclinical studies and limited clinical evidence suggest curcumin supports bone health by promoting osteoblast activity and inhibiting osteoclastogenesis. A small clinical study found a 7% improvement in bone density over 6 months with a curcumin phytosome supplement. A 2025 systematic review and meta-analysis of animal studies confirmed significant BMD improvements.

Preclinical studies show vanadium accumulates in bone and stimulates osteoblast differentiation while inhibiting osteoclast activity, with in vitro evidence of bone cell proliferation. Animal studies involving vanadium-deficient goats showed skeletal deformations. No human RCT evidence demonstrates that vanadium supplementation increases bone mineral density.

The relationship between vitamin A and bone density is scientifically documented but complex and bidirectional. A 2024 cross-sectional study of 1,536 US adults (NHANES) found higher vitamin A intake was associated with lower odds of osteoporosis (OR 0.85 for highest vs. lowest tertile). However, high retinol intake has also been associated with increased fracture risk in some cohort studies, and preclinical data show excess vitamin A reduces cortical bone formation. The overall evidence is contested.

Low vitamin B12 is associated with reduced bone mineral density (BMD) in several observational studies, including the Framingham Osteoporosis Study. Mechanistically, B12 deficiency raises homocysteine, which interferes with collagen cross-linking in bone. However, intervention trials have produced inconsistent results, with most RCTs showing no significant overall benefit of B12 supplementation on BMD.

Vitamin C (ascorbic acid) is an obligatory cofactor for collagen prolyl and lysyl hydroxylases, the enzymes required for collagen crosslinking in the bone matrix. Deficiency causes scurvy with characteristic bone fragility. Epidemiological studies (Framingham Osteoporosis Study, NHANES) associate higher vitamin C intake with greater BMD at the femoral neck and spine, and it is mechanistically essential for the collagen scaffold underlying bone mineralization.

Vitamin D is critical for calcium absorption and bone mineralization. Deficiency causes rickets in children and osteomalacia in adults. Combined calcium and vitamin D supplementation has been shown in RCTs to attenuate bone loss at the hip and lumbar spine, and vitamin D deficiency is strongly associated with lower BMD and higher fracture risk.

Vitamin D3 (cholecalciferol), the animal-derived and skin-synthesized form of vitamin D, is more potent than D2 in raising serum 25(OH)D levels. RCTs consistently show that vitamin D3 combined with calcium reduces bone loss, particularly at the hip and spine, and it is endorsed by WHO, NIH, and major osteoporosis guidelines as the preferred supplemental form for bone health.

Vitamin K is required for the carboxylation of osteocalcin, a key bone matrix protein that enables calcium binding in bone mineral. A 2022 systematic review and meta-analysis of 20 RCTs found that vitamin K supplementation increased lumbar spine BMD and significantly improved osteocalcin carboxylation markers, with particular benefit in postmenopausal women.

Wasabi leafstalk contains p-hydroxycinnamic acid (HCA), an osteogenic factor identified in preclinical research that stimulates osteoblastic bone formation and suppresses osteoclastic bone resorption in vitro. Oral administration of HCA restored bone loss in ovariectomized and diabetic animal models. Wasabi leafstalk extract also suppressed osteoclast-like cell formation stimulated by parathyroid hormone.

Watercress is a significant dietary source of vitamin K1, and a meta-analysis of RCTs confirms that vitamin K combined with calcium has a positive effect on lumbar bone mineral density (BMD) and reduces fracture risk. The evidence links watercress's nutrient composition—vitamin K1 and calcium—to documented BMD effects, though no watercress-specific bone density RCT exists.

Preclinical evidence shows XOS can improve bone formation parameters in rodent models. XOS was demonstrated to reduce systemic inflammation, increase trabecular thickness, reduce osteoclasts and active erosive surfaces, and restore mineral deposition and bone formation rates in male Wistar rats. Human clinical evidence is not yet established.

A cross-sectional observational study of 292 postmenopausal women found that habitual yerba mate drinkers had significantly higher lumbar spine and femoral neck BMD. A follow-up study also found positive volumetric BMD measures. The mechanism is unclear but is not attributable to caffeine content alone.

A randomized, double-blind, placebo-controlled human clinical trial of PMA-zeolite clinoptilolite in osteoporosis patients demonstrated increased bone mineral density, elevated bone formation markers, reduced pain, and improved quality of life versus placebo. Parallel ovariectomized rat model data confirmed improved bone histomorphometric parameters. This is supported by a 4-year clinical trial tracking blood mineral changes in osteoporosis patients.

Zinc is an essential cofactor for alkaline phosphatase and enzymes critical to bone matrix synthesis and remodeling. Clinical evidence links zinc deficiency with reduced BMD, and supplementation studies suggest zinc supports bone formation markers. It is recognized by the NIH ODS and National Academy of Sciences as important for bone health.

Alfalfa contains calcium, magnesium, vitamin K, vitamin D2, and vitamin D3, all relevant to bone metabolism. Its phytoestrogens (genistein analog activity) have been linked to bone preservation in estrogen-deficient states in animal and some human studies using purified genistein. Direct clinical evidence for alfalfa itself improving bone density is absent.

Almonds contain multiple nutrients implicated in bone health including calcium, magnesium, phosphorus, and vitamin E. Preclinical data and epidemiological associations link almond's vitamin E content to bone mineral density, but direct clinical RCTs specifically examining almonds and bone density are lacking, and further clinical research is recommended.

Cloves are a significant dietary source of manganese, a mineral essential for bone formation and metabolism-related enzyme activity. Traditional medicine systems note clove's role in musculoskeletal support, though human clinical trial data on bone density outcomes are absent.

Dulse provides calcium, magnesium, iron, potassium, and phosphorus—key minerals for bone matrix formation and maintenance. Nutritional analyses confirm 100 g dried dulse contains approximately 370 mg calcium and 310 mg magnesium, exceeding many land vegetables. Traditional use in mineral-rich seaweed diets has long supported skeletal health in coastal populations, though no dulse-specific bone density clinical trial has been conducted.

Traditional Ayurvedic medicine uses amla for bone health, and its calcium, vitamin C, and antioxidant content are mechanistically supportive of bone density. Myhealthopedia cites amla as helping bone density. No dedicated human clinical trials on bone mineral density outcomes have been identified.

Haliotis shell is rich in calcium carbonate and is traditionally used in TCM for conditions related to bone weakness. In vitro research shows abalone gastrointestinal digests can promote osteoblast activity, but no human bone density trials exist for haliotis specifically.

Nettle leaves are rich in calcium, magnesium, silica, vitamin K, and flavonoids—nutrients relevant to bone metabolism. Preclinical data (animal and in vitro) suggest nettle extract promotes osteoblast activity and inhibits osteoclasts, accelerating bone formation. Traditional medicine systems including Moroccan herbalism use nettle for bone and joint disorders. No human clinical trials on bone density endpoints have been identified.

Purslane is a notable plant source of calcium (65 mg/100 g) and magnesium (68 mg/100 g)—two minerals essential for bone metabolism—and traditional use for osteoporosis is documented. No RCTs measuring bone density outcomes with purslane supplementation were identified; the relationship is based on nutritional composition and traditional use.

Traditional Southeast Asian use of Tongkat Ali includes treatment for osteoporosis and bone-related conditions. Preclinical studies show anti-osteoporotic activity including prevention of bone calcium loss in animal models, stimulation of osteoblast growth, and enhanced alkaline phosphatase activity. Testosterone normalization (clinically demonstrated with TA) is known to support bone density, but no human clinical trial has directly measured bone mineral density outcomes with Tongkat Ali supplementation.